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ABSTRACT 
Background: Respiratory tract infections (RTls) are considered to be the 
primary reason for prescribing antibiotics in community practice, accounting for 
75% of prescribed antibiotics. Only some of these conditions, acute non 
pneumonic RTls (ARTls), are the focus of this dissertation. ARTls include 
acute cases of nasopharyngitis (common cold), sinusitis, pharyngitis (sore 
throat), laryngitis, and bronchitis. These conditions are, in many cases, caused 
by a viru~ and they usually resolve naturally without the use of any medication. 
Objectives: Many studies have demonstrated the inappropriate overutilization 
of antibiotics in certain ARTls. This practice may be associated with high 
unnecessary costs and potential for resistance from such use. Factors behind 
this practice are many. Some have been studied and many still need more 
exploration. The objectives of this study were to a) provide specific information 
on the influence of prescription drug coverage on antibiotic utilization; b) the 
influence of prescribing antibiotics on patient reported satisfaction; c) explore 
the effect of drug copayment on prescribing of antibiotics. The study also 
estimated the total cost in dollars that may be saved from the direct cost of 
antibiotics, to both the insurers and patients, when paying for these 
medications that may be used inappropriately. 
Methods: A cross-sectional retrospective study of prescription events 
associated with different ARTls was identified from the Household Component 
(HC) of the 1996 Medical Expenditure Panel Survey (MEPS). Descriptive and 
logistic regression analyses were conducted to explore the relationship 
between the different variables in the study with antibiotic utilization. The 
perspective taken in these studies was that of a healthcare insurer. 
Results: The study found that the likelihood of being prescribed an antibiotic, 
' which may be of high cost and unnecessary, is greater when patients have 
prescription drug coverage. However, no effects were related to drug 
copayment on antibiotic utilization. The study also suggests that in this 
population the level of patient satisfaction with the quality of care provided is 
not influenced by whether antibiotics are prescribed or not. It was also found 
that millions of dollars may be wasted yearly on these medications. 
Conclusion: The findings from this study provide more insight to insurers and 
designers of drug coverage plans, who should closely monitor prescribing 
patterns for these conditions to avoid unnecessary cost as well as resistance 
from such antibiotics. They should not focus on antibiotic prescribing as a 
means of patient satisfaction, but on the appropriate use of such antibiotics 
and the avoidance of unwanted effects. More research is needed to examine 
the effect of the different copayment tier systems introduced in the last couple 
of years on the utilization of these drugs and whether they may help reduce 
the inappropriate use of these drugs. 
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PREFACE 
This dissertation is prepared following the manuscript format, and it consists of 
two parts. Part 1 contains three studies that form the main body of the 
dissertation. Part 2 contains the appendices required by the University but are 
not usually presented in a published paper. 
Part 1 includes: 
Study 1: The Influence of Prescription Drug Coverage on Antibiotic Utilization 
in Acute Respiratory Tract Infections. 
Study 2: The Influence of Antibiotic Utilization in Acute Respiratory Tract 
Infections on Patient Reported Satisfaction with Quality of Care. 
Study 3: The Influence of Medication Copayments on Antibiotic Utilization in 
Acute Respiratory Tract Infections. 
Part 2 includes: 
Appendix A. Background and review of the problem 
Appendix B. Details of the methods used 
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in Acute Respiratory Tract Infections. 
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Infections on Patient Reported Satisfaction with Quality of Care. 
' Study 3: The Influence of Medication Copayments on Antibiotic Utilization in 
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The Influence of Prescription Drug Coverage on Antibiotic Utilization in 
Acute Respiratory Tract Infections 
Abstract 
Background: Recognizing the effect of prescription drug coverage on the 
patient's ability to obtain prescription drugs is crucial and may play an 
important role in the health care decision making process due to the 
' 
associated cost and the potential for misutilization. It is the objective of this 
study to provide specific information on the influence of prescription drug 
coverage on antibiotic utilization in acute nonpneumonic respiratory tract 
infections (ARTls). 
Methods: A retrospective study of (N=2534) prescription events associated 
with ARTls have been identified from the Household Component (HC) of the 
1996 Medical Expenditure Panel Survey (MEPS). Cases selected included 
acute nasopharyngitis (common cold), acute sinusitis, acute pharyngitis, acute 
tonsillitis, acute laryngitis and tracheitis, acute unspecified upper respiratory 
tract infections, and acute bronchitis and bronchiolitis. Antibiotic use and 
associated costs were determined by selecting oral antibiotics and the sum of 
payments associated with each prescription. Logistic regression was utilized to 
evaluate prescription drug coverage effect on prescribing an antibiotic and on 
the type of antibiotic prescribed. 
2 
Results: In 1996, antibiotics accounted for 4 7% of the prescription events for 
ARTIS, of which 29% were for high cost antibiotics. When compared to 
patients with private prescription drug coverage, patients with no drug 
coverage were less likely to be prescribed an antibiotic (OR=0.49; 95% Cl = 
0.37 _ 0.65). The chance of getting a high cost antibiotic was also lower in 
events associated with no drug coverage (OR=0.1 O; 95% Cl = 0.05 - 0.19). 
No significant difference was shown between public and private coverage. 
' Conclusion: The results of the study indicate that the rates of prescribing an 
antibiotic for ARTls are still high, and that the likelihood of being prescribed an 
antibiotic, which may be of high cost and unnecessary, is greater when 
patients have prescription drug coverage. Providers of such coverage should 
closely monitor prescribing patterns for these conditions to avoid unnecessary 
cost as well as resistance from such antibiotics. 
3 
Introduction: 
Respiratory tract infections (RTls) are considered to be the leading cause of 
prescribing antibiotics in community practice, accounting for 75% of prescribed 
antibiotics. [1] In the year 1992, there were approximately 57 million 
prescriptions for antibiotics in the United States with colds, bronchitis and 
upper RTls accounted to 12 million of the total prescriptions. [2] Only acute 
nonpneumonic respiratory tract infections (ARTls) was the focus of this study. 
ARTls include conditions where antibiotics are generally considered to be 
inappropriate such as in acute nasopharyngitis (common cold), acute 
unspecified upper respiratory tract infections, acute bronchitis, and acute 
laryngitis and tracheitis.[3, 4] Most of these conditions are not life threatening 
and are usually caused by a virus.[3] Even when bacteria are the causative 
pathogen, the illness, in most cases, resolves naturally and rapidly.[4, 5] It is 
also important to note that antibiotics have not been shown to improve the 
clinical outcome of patients with these conditions.[2, 6] 
Other ARTls conditions like acute pharyngitis and acute sinusitis, antibiotics 
are in many cases not recommended, however it may be beneficial in some 
patients,.[3] Even when prescribed an antibiotic the choice should be for a 
narrow spectrum, low cost antibiotic (e.g., penicillin) to avoid the unnecessary 
cost and the potential of resistance.[4] The reasons for prescribing an 
4 
antibiotic in acute pharyngitis is because it is hard to differentiate between 
streptococcal infection versus a viral infection, and also to prevent 
complications, such as acute rheumatic fever and acute glomerulonephritis.[4] 
However, the potential of being infected with the bacteria that causes 
rheumatic fever is rare in many population,[3, 4] and for acute 
glomerulonephritis, one meta-analysis showed that the rates have not been 
reduced by the use of antibiotic.[?] It is also, important to note that the natural 
rates for resolution without any complications are >90% for streptococcal 
' pharyngitis,[8] and approximately 69% for acute sinusitis.[9] 
Many studies have demonstrated the inappropriate overutilization of antibiotics 
in certain acute RTls. [10-12] In 1998 one study estimated that 76 million office 
visits for acute RTls resulted in 41 million antibiotic prescriptions. This was 
55% (22.6 million) more prescriptions than were expected to be used, with an 
associated cost of approximately $726 million.[13] Another study estimated 
that between 1989 and 1999 there were 6.7 million annual office visits by sore 
throat (acute pharyngitis) patients, where approximately three quarters of 
adults (73%) were prescribed an antibiotic and 68% of the prescribed 
antibiotics were for non recommended use. The study also showed that broad 
spectrum and more expensive antibiotics are frequently used.[14]. 
Recent studies have shown that the rate of prescribing inappropriate 
antibiotics has decreased.[15, 16] However, the rate is still high and is 
5 
associated with high unnecessary costs, as illustrated in the previous 
paragraph. The practice is also associated with the potential and risk for 
resistance from such antibiotics, which is becoming an epidemic and a global 
problem.[17-19] 
Recognizing the problem has led to many studies that looked at factors 
leading to the inappropriate antibiotic prescribing. Studies that examined 
patients' preferences suggest that they are expecting to receive an antibiotic 
' and consequentially pressure their physician to prescribe one. Patients may 
also be financially responsible for a low copayment or no copayment which 
may give them more incentive to fill the prescription.[20, 21] Physicians, on the 
other hand, try to meet the expectation of their patients and attempt to avoid 
any liability in case of a treatment failure, leading them to prescribe broad 
spectrum antibiotics.[22] Other factors may include the health care system 
structure, including formularies and prescribing restrictions.[23] Directed 
advertising and marketing to physicians and consumers by pharmaceutical 
companies may also lead to more prescription of high cost broad spectrum 
antibiotics. [24] 
The influence of prescription drug coverage on the utilization is one of the 
potential factors that affect antibiotic prescribing. Many studies have 
demonstrated the influence of prescription drug coverage on the drug 
Utilization in different patient populations.[25-31] Many of these studies 
6 
showed an increase use of medications when the study population had 
prescription drug coverage. However, some suggest that by not having the 
coverage, underutilization of essential drugs may occur.[32] 
Studies that examine the effect of drug coverage on the utilization of drugs in 
general and in the utilization of antibiotics in ARTls in particular, are becoming 
more important, knowing that the strong possibility of having a drug benefit 
plan for the Medicare population and with different health care plans offering 
drug coverage. 
The objective of this study is to explore the influence of prescription drug 
coverage on the utilization, both in terms of frequency and type, of antibiotics 
in ARTls, where studies are limited. The study will also identify the effect of 
other potential relevant factors such as socioeconomics and demographics. 
The hypothesis is that the frequency and type of antibiotics prescribed for 
ARTls are greatly influenced by whether or not the person has a drug 
coverage policy. The results of this study will be of great value for policy and 
decision makers who are responsible for setting such benefits. 
7 
,Methods: 
Data source: 
The source of data in this study was the 1996 Household Component (HC) of 
the Medical expenditure Panel Survey (MEPS). MEPS is a national database 
that is cosponsored by the Agency for Healthcare Research and Quality 
(AHRQ), and the National Center of Health Statistics (NCHS). The HC 
contains many files that are publicly available, and it contains medical 
' 
expenditure data at both the person and household level and when weighted, 
provides nationally representative estimates of health care access, 
satisfaction, utilization, quality, expenditure, source of payments, and 
insurance coverage for the US civilian non-institutionalized population.[33] 
Sampling for the HC is drawn from 10,500 household participants in the 1995 
National Health Interview Survey (NHIS), conducted by NCHS. NHIS provides 
a nationally representative sample of the U.S. civilian non-institutionalized 
population, with oversampling of blacks and hispanics.[33] 
The HC files that have been used in the analysis are the 1996 full year 
consolidated data and 1996 prescribed medicines event. The full year 
consolidated file contains one record for each of 22,601 persons and when 
Weighted can be used to make national estimates of utilization and 
expenditures for calendar year 1996.[34] The prescribed medicine events file 
8 
provides detailed information on 147,308 prescribed medicine events of 
household-reported prescribed medicines, and when weighted, can be used to 
make estimates of prescribed medicine utilization and expenditures for 
calendar year 1996. In addition the prescribed medicine file contains 
household reported characteristics and medical conditions associated with 
prescribed medicine.[35] 
For the purpose of this analysis both files have been merged. This allowed us 
' to append personal characteristics such as demographic or health insurance 
coverage to each prescribed medicine record. Information about merging 
came from the data codebooks.[34, 35] 
Study population: 
The study population included cases of ARTls identified by the International 
Classification of Diseases, Ninth Revision Clinical modification codes (ICD-9 
codes), that were associated with prescribed medicine events. Each 
prescribed medication was associated with up to three ICD-9 codes and was 
reported by patients, which then were conformed by pharmacy records. The 
study has excluded prescription events with more than one ICD-9 code to 
assure that the prescription medicine of interest is for a particular ICD-9 code. 
The total prescription events (unit of interest) that were associated with these 
cases were (N=2534). Conditions selected included: acute nasopharyngitis 
9 
(common cold) (ICD-9 460), acute sinusitis (ICD-9 461 ), acute pharyngitis 
(ICD-9 462), acute tonsillitis (ICD-9 463), acute laryngitis and tracheitis (ICD-9 
464), acute unspecified upper RTls (ICD-9 465), and acute bronchitis (ICD-9 
465). 
Definition of variables: 
Dependent Variables (DVs): 
' The first dependent variable of interest was defined as being prescribed an 
antibiotic or not, and only oral antibiotics were included in the analysis. The 
second dependent variable was defined as the type of antibiotic being 
received (i.e., high or low cost antibiotic). Antibiotic type was created by 
summing payments for each antibiotic prescribed and calculating the median 
cost. An antibiotic is considered to be high cost if the median cost was more 
than $30.00, and was considered low cost if the antibiotic median cost was 
$30.00 or less. 
Independent Variables (IV): 
The main variable of interest was prescription drug coverage, which was 
categorized into public, private or no drug coverage. An event is considered to 
have public drug coverage if the event was paid for by one of the following 
source of payments: Medicaid, Medicare, Veterans Affairs, 
10 
CHAMPUS/CHAMPV, other federal, state and local government, or other 
public. Private drug coverage is considered if the event is paid for by any of 
the following source of payments: private insurance, workers compensation, 
other insurance, or other private. No coverage was considered if the event 
was paid for by the person or any family member. 
Other Variables: 
Demographic and socioeconomic characteristics of the study population 
examined any possible effect on the utilization of antibiotic and whether they 
may be potential confounders. Variables in the study included: sex, race, age, 
census region, marital status, years of education, employment status, poverty 
level, the amount paid by the person or a family member for a medication (i.e., 
antibiotic) . 
Statistical analysis: 
A descriptive analysis of the study population was conducted. A chi-square 
test was carried out to examine the difference between the various 
independent variables on antibiotic utilization, the p-values are reported. The 
level of significant used for a p-value was alpha=0.05. 
Logistic regression analysis was used to determine the independent effect 
(relative risk) of different types of prescription drug coverage insurance on the 
11 
utilization of antibiotics (i.e., frequency and/or types). The final logistic 
regression model was run while controlling for confounders. Odds ratios and 
the gs% confidence interval were reported. 
Several techniques were used to develop the final logistic regression model. 
First, variables used in the study were dichotomized and dummy variables 
created for the following variables: drug coverage, age, census region, poverty 
status, and self/family payment of prescription drugs. Second, univariate 
logistic regression was used to evaluate the relative contribution of each 
independent variable on predicting antibiotics utilization. Third, assessment of 
possible interaction terms (effect modifiers) was done between the primary 
independent variable (drug coverage insurance) and all other variables. Three, 
two, and one term interactions were completed and the decision was made on 
whether there was an interaction by examining the log likelihood ratios in the 
chunk test. 
The fourth technique used was testing for multi-collinearity and that was 
completed to examine the highly correlated variables and, if necessary, 
remove any variable from the model. That was accomplished by examining the 
condition index in the SAS output. Finally, testing for potential confounders 
that may influence our final model was carried out by comparing the B 
(coefficient) of the primary independent variable (prescription drug coverage) 
of the full model to each reduced model (i.e., a model missing on variable). 
12 
All statistical analysis were carried out using SAS version 8.1 (SAS Institute, 
Cary, North Carolina) and SUDAAN software package (Research Triangle 
Institute, Research Triangle Park, North Carolina), both licensed to the 
University of Rhode Island. The results of the study have been weighted to 
generate 1996 national estimates of the influence of prescription drug 
coverage on the utilization of antibiotics in ARTls. Many references for SAS 
and SUDAAN programming, methodology, and interpreting results have been 
used.(36-40] 
' 
Results: 
The number of cases of ARTls included in the study is presented in Table1, 
were around 57% of the cases were identified as the common cold. The table 
also shows the rate of prescribing antibiotic in each ARTls condition and the 
overall rate of prescribing an antibiotic in the study population which was 
around 47% of the total events. 
Table 2a contains a list of oral antibiotics used in the study population where 
low cost antibiotics (i.e., median cost less than $30.00) are mainly generics 
and that of high cost antibiotics (i.e., median cost of $30.00 or more) are 
brands. The high cost antibiotics were around 29% of the total antibiotics 
prescribed to patients with ARTls (Table 2b). 
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The demographic and socioeconomic characteristics of the study population 
are presented in Table 3. This table indicates that, in 1996, 34% of the ARTls 
events were associated with no drug coverage, 50% with private drug 
coverage and 16% with public drug coverage. The table also shows that 84% 
of events were for white Americans versus only 16% for non-whites. 
Approximately 44% of the cases were for children under the age of 17 years 
old and 63% of events had moderate to high income. Due to missing 
observations that may affect the analysis, two variables, years of education 
' 
and employment status, have been removed from the analysis. 
Table 4 illustrates the results of the cross-tabulation and the chi-square of all 
the variables in the study against antibiotic use and type. The unweighted chi-
square test showed that when looking at the use of antibiotic (DV1 ), the 
variables that showed a significant difference in the study population were 
prescription drug coverage, race, age, poverty status, and self/family payment 
of prescription drugs. However, when the data were weighted using SUDAAN, 
the variables were shown to be significant were the prescription drug 
coverage, race, poverty status, and self/family payment of prescription drugs. 
Table 4 also shows that when the same unweighted chi-square test was 
carried out on the type of antibiotic used (DV2) the variables that showed a 
significant chi-square test were the prescription drug coverage, sex, age, 
census region, poverty status, and self/family payment of prescription drugs. 
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However, when the data were weighted using SUDAAN, the variables that 
showed to significant, were only the prescription drug coverage, poverty 
status, and self/family payment of prescription drugs. 
The univariate logistic regression analysis showed that many of the variables 
had an independent effect on both antibiotic use and type. Interaction 
assessment conducted for both dependent variables have concluded that no 
interaction terms exist between the variables. The analysis also showed that 
' no highly correlated variables exist. Testing for confounders concluded that 
when looking at the use of antibiotics, race, poverty status and self/family 
payments of antibiotic are potential confounders. However, when examining 
the type of antibiotic used, poverty status and self/family payments of antibiotic 
are potential confounders. 
The final logistic model shown in Table 5 indicated that, in 1996, before 
controlling for confounders, ARTls events with both public drug coverage and 
with no drug coverage were at a significant lower risk (i.e., chance) of 
receiving an antibiotic than in events with private coverage (Public: OR=0.47; 
95% Cl= 0.34 - 0.65) with a p-value of 0.000 and (No coverage: OR=0.66; 
95% Cl=0.52 - 0.83) with a p-value of 0.0004. However, when controlling 
(adjusting) for potential confounders (i.e., race, poverty status, and self or 
family payments of antibiotics), only events associated with no drug coverage 
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showed a significant lower chance of receiving an antibiotic (OR=0.49; 95% Cl 
= 0.37 _ 0.65) with a p-value of 0.000. 
The other logistic model shown in Table 6 also suggested that, in 1996, the 
chance of getting a high cost antibiotic before controlling for confounders, was 
also lower in events associated with public coverage events when compared 
to privet drug coverage (Public: OR=0.48; 95% Cl=0.27 - 0.48) with a p-value 
of 0.0097 and no significant different was seen in events with no drug 
' coverage (OR=0.75; 95% Cl=0.49- 1.13) with a p-value of 0.1678. However, 
when controlling for potential confounders (i.e., poverty status and self or 
family payments of antibiotics) the opposite results were found in that the 
chance of getting a high cost antibiotic was only lower in events with no drug 
coverage (OR=0.1 O; 95% Cl = 0.05 - 0.19) with a p-value of 0.000. No 
significant difference was observed between public and private coverage. 
Discussion: 
The study demonstrates that the rate of prescribing an antibiotic for ARTls is 
still high, and in 1996 it was around 13.6 million prescription, in which around 
29% were for high cost broad spectrum antibiotics which should not be used 
even if antibiotics may be recommended since in many ARTls cases they are 
not the drug of choice[4]. These prescriptions are, in many cases, considered 
unnecessary and may be associated with excessive costs and bacterial 
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. t nt that can be easily avoided with a better management of such events. 
res1s a 
That can be accomplished by a better understanding of the different 
socioeconomic and behavioral factors behind such a problem. 
The study also, demonstrated that the prescription drug coverage is an 
important and a key factor having a significant role in the utilization of 
antibiotics in ARTls. Results showed that prescription drug coverage is 
associated with an increased utilization of antibiotics, and that was also 
' 
associated with more consumption of high cost antibiotics. Findings are 
consistent with many of the studies that indicate the effect of having a drug 
coverage on the increase utilization of drugs in different diseases and 
populations.[26-29, 41] However, this study is different in that it looks at the 
utilization of antibiotics in a specific group of conditions (i.e., ARTls), using a 
national database allowing us to make national estimates of utilization. 
The study illustrates the need for similar studies, which is becoming more 
important for many reasons. First, the potential of overutilization of 
unnecessary medications with the unwanted risk associated with it use (e.g., 
antibiotic resistance). Second, the need to lower the increasing cost of the 
health care system in regard to medication utilization which is about 13.1 % of 
the total health care cost. [42] Finally, these kinds of studies will help many 
managed care organization and health insurers who are trying to lower their 
costs without affecting the quality of care they provide and will also help the 
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United State government especially with the potential of having a Medicare 
prescription drug plan. 
A number of potential limitations are associated with this study. First, the data 
used in the analysis does not provide information about the different benefits 
associated with each prescription drug plan, making it hard to examine at the 
influence of the degree of benefits (i.e., generosity level) on the utilization of 
antibiotics. Second, the study is cross-sectional in nature and may prevent 
' 
analysts from capturing the influence of any change in the drug coverage 
policy over time. Third, the diagnosis information are imputed based on what 
was reported by the patient or the patient guardian, which may be biased (i.e., 
recall bias). Finally, the data does not provide information regarding the 
causative agent, whether it is a viral or bacterial, and it also does not provide a 
history of any antibiotic used. 
Despite these limitations the study was able to show a significant result 
because we think that is reflecting what is really happening in regard of 
prescription practices in different clinical settings throughout the country. The 
results are very helpful to policy and decision makers, both in the government 
and the private sector, who are in charge in making and designing prescription 
drug benefits. It also illustrated that prescription drug coverage without the 
proper management may be reasons for misutilization and increasing cost that 
can be avoided. 
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Future studies using recent released MEPS or any other similar dataset 
should examine the effect of the different types of drug coverage on antibiotics 
utilization in ARTls and if possible to compare between the change in trend 
over time. It is also important to explore the effect of drug coverage in other 
disease states and conditions, which will be of great value for people in charge 
of designing drug benefit plans in both private and public sectors. 
Conclusion: 
The results of the study indicate that the rates of prescribing an antibiotic for 
ARTls are still high, and that the likelihood of being prescribed an antibiotic, 
which may be of high cost and unnecessary, is greater when patients have 
prescription drug coverage. Providers of such coverage should closely monitor 
prescribing patterns for these conditions to avoid unnecessary cost and 
consequently, resistance from such antibiotics. 
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T ble1.1 study populatio~ ~f Acut~ Respiratory tract. infectio~s (ARTls) events and :a rate of antibiotic rescnb1n , we1 hted to make national estimates. 
Unweighted Weighted (in millions) 
(N=2534) (N=29.28) 
N(%) N(%) AB%* 
ARTls conditions 
Acute nasopharyngitis (common cold) 1536 (60.6) 16.60 (56.7) 38.1 
Acute URI multiple sites/NOS 264 (10.4) 3.63 (12.4) 52.1 
Acute bronchitis and bronchiolitis 74 (2.9) 1.06 (3.6) 38.9 
Acute tol'\sillitis 165 (6.5) 1.74 (5.9) 69.9 
Acute laryngitis and tracheitis 53 (2.1) 0.782 (2.6) 41.46 
Acute sinusitis 17 (0.6) 0.218 (0.7) 82.31 
Acute pharyngitis 425 (16.7) 5.21 (17.8) 62.03 
Antibiotic prescribing rates 
No antibiotic 1386 (54.7) 15.67 (53.5) 
NA** 
Antibiotic 1148 (45.3) 13.60 (46.4) NA 
* AB%=rate of antibiotic prescriptions in the different ARTls 
**NA=not applicable 
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Table 1.2a Classificatio.n of t~e reported oral antibiotics used in a study population of 
Acute Res irato tract 1nfect1ons ARTls events. 
Low cost High cost 
if median cost is $30.00 & less 
amoxicillin 
ampicillin 
penicillins 
erythromycin 
SMZ!TMP 
ceftibuten (Cedax®) 
cephradine 
cephalexin (Keftab®, Keflex®) 
clindamycin 
doxycycline 
' 
if median cost is more than $30.00 
Augmentin® 
Zithromax® 
Cipro® 
Biaxin® 
cefaclor (Ceclor®) 
cefprozil (Cefzil®) 
cefadroxil 
cefuroxime (Ceftin®) 
loracarbef (Lorabid®) 
nitrofurantoin 
cefixime (Suprax®) 
dirithromycin (Dynabac®) 
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T ble 1.2b Types of antibiotics used in a study population of Acute Respiratory tract 
in~ections ARTls events, wei hted to make national estimates. 
'Low cost antibiotics 
High cost antibiotics 
Unweighted 
(N=1148) 
N(%) 
850 (74.04) 
298 (25.96) 
Weighted (in millions) 
(N=13.60) 
N(%) 
9.64 (70.91) 
3.95 (29.09) 
Note: The high/low classification was based on the median cost of the sum of payments for 
;;;;; prescribed antibiotic used in the study population. 
' 
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bl 1 3 Demographic and Socioeconomic characteristics of a study population of !~ut: Respiratory tract infections (ARTls) events, weighted to make national 
estimates. 
Unweighted Weighted (in millions) 
(N=2534) (N=29.28) 
~riables N(%l N (%1 
Prescription drug coverage 
1120 (44.20) 14.57 (49.78) Private 
Public 515 (20.32) 4.61 (15.75) 
No coverage 899 (35.48) 10.09 (34.47) 
Sex 
1070 (42.23) 12.47(42.62) Male 
Female 1464 (57.77) 16.80 (57.38) 
Race ' 
White 2087 (82.36) 24.70(84.36) 
Non-white 447 (17.64) 4.57 (15.64) 
Age 
Children (0-17) 1219 (48.18) 12.98 (44.46) 
18-44 yrs 675 (26.68) 8.55 (29.29) 
45-90 yrs 636 (25.14) 7.66 (26.25) 
Census Region 
Northeast 438 (17.31) 5.15 (17.65) 
Midwest 587 (23.20) 7.51 (25.74) 
South 937 (37.04) 10.63 (36.43) 
West 568 (22.45) 5.89 (20.18) 
Marital Status 
Married 760 (30.04) 9.02 (30.90) 
Not married 1770 (69.96) 20.18 (69.10) 
Income (poverty line) 
Negative or poor 626 (24.70) 5.23 (17.87) 
Near poor 168 (6.63) 1.59 (5.44) 
Low income 352 (13.89) 4.24 (14.50) 
Middle income 731 (28.85) 9.40 (32.12) 
High income 657 (25.93) 8.80 (30.06) 
Self/family payment of antibiotic 
$0 544 (21.47) 5.12 (17.52) 
>$0 -< $5 505 (19.93) 6.05 (20.70) 
$5 - <$10 874 (34.49) 10.58 (36.17) 
$10 & more 611 _(_24.111 7.50 _(_25.621 
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1 4 Bivariate analysis for both the antibiotic usage and type with all the other Ta~l~I ~in a study population of Acute Respiratory tract infections (ARTls) events, 
vana e · t' t 
. hted to make national es 1ma es. ~eiQ! Antibiotic used* Antibiotic type** 
~riables Yes (%l No (%l High (%l Low (%l 
Prescription drug Coverage 
21.31 15.07 35.45 Any Private 22.89 
Any Public 7.54 12.79 2.96 13.68 
No coverage 14.88 20.60 7.93 24.91 
Sex 18.82 23.4 12.11 29.44 Male 
Female 26.48 31.29 13.85 44.60 
Race 
38.95 43.41 23.08 62.89 White 
Non-white 6.35 11.29 2.87 11 .15 
Age 
chndren (0-17) 22.61 25.57 12.14 37.82 
18-44 yrs 12.33 14.35 6.38 20.87 
45-90 yrs 10.32 14.82 7.34 15.46 
Census Region 
Northeast 8.5 8.81 5.94 12.84 
Midwest 10.43 12.77 6.2 16.86 
South 16.76 20.28 9.96 27.07 
West 9.57 12.89 3.76 17.38 
Marital Status 
Married 13.68 16.36 8.82 21.4 
Not married 31.58 38.38 17.03 52.75 
Poverty line:t:: 
Negative or poor 9.00 15.71 3.83 16.03 
Near poor 3.24 3.39 0.7 6.45 
Low income 6.04 7.85 3.48 9.84 
Middle income 14.7 14.09 9.41 23.17 
High income 12.27 13.65 8.54 18.55 
Self/family payment of antibiotic:t:: 
$0 8.84 12.63 3.66 15.85 
>$0 -< $5 6.12 13.81 2.18 11.32 
$5 - <$10 16.22 18.27 3.57 32.23 
$10 & more 14.13 9.98 16.55 14.63 
~eve/ of ~i~nificant used in this chi-square analysis was p-va/ue of 0. 05. 
t P;escript1on drug coverage, race, poverty line and self/family payment of antibiotics showed 
.~ ave significant p-values. 
h Pre~criJ?~ion drug coverage, poverty line and self/family payment of antibiotics showed to 
ave s1gnif1cant p-values. 
:tThe variable showed to be significant even after dichotomizing. 
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bl 1.5 Final logistic model for the ~ffect of prescription drug coverage on Tafb~otic utilization in a study population of Acute Respiratory tract infections (ARTls) 
an 
1 ts wei hted to make national estimates. 
even • 
OR (95% Cl) 
Prescription drug Coverage 
Without controlling for confounders 
Private 
Public 
No coverage 
1.00 
0.47 (0.34 to 0.65) 
0.66 (0.52 to 0.83) 
Controlling for potential confounders* 
Private 
Public 
No coverage 
1.00 
0.67 (0.43 to 1.06) 
0.49 (0.37 to 0.65) 
Note: OR=odd ratios, 95% Cl= 95% confidence interval 
P- value 
reference 
0.0000 
0.0004 
reference 
0.0895 
0.0000 
*Potential confounders were race, poverty status and self/family payment of antibiotic. 
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Table 1.6 Final logi~t!c mo?el for the effect of. prescription drug ~overage on 
ty of antibiotic utilized in a study population of Acute Respiratory tract infections 
:~Tis events, wei hted to make national estimates. 
OR (95% Cl) 
Prescription drug Coverage 
Without controlling for confounders 
Private 
Public 
No coverage 
1.00 
0.48 (0.27 to 0. 48) 
0.75 (0.49 to 1.13) 
Controlling for potential confounders 
Priv~te 
Public 
No coverage 
1.00 
1.23 (0.47 to 3.22) 
0.10 (0.05 to 0.19) 
P- value 
reference 
0.0097 
0.1678 
reference 
0.6748 
0.0000 
Note: OR=odd ratios, 95% Cl= 95% confidence interval 
*POfential confounders were poverty Status and self/family payment of antibiotic. 
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The Influence of Antibiotic Utilization in Acute Respiratory Tract 
Infections on Patient Reported Satisfaction with Quality of Care 
Abstract 
Background: In recent years, patients reporting satisfaction with their quality 
of care has been of a greater interest to healthcare providers and to users of 
the heath care system. Such information is important and may play a role in 
the decision roade by patients when choosing their provider and by physicians 
when making clinical decisions about prescribing antibiotics. 
Objective: It is the objective of this study to provide specific information on the 
influence of prescribing antibiotics to patients with acute respiratory tract 
infections (ARTls) on patients reporting satisfaction with their quality of care. 
Methods: A total of 514 patients with ARTls were identified from the 1996 
Medical Expenditure Panel Survey (MEPS). Cases selected were for patients 
having a prescription record and who answered the satisfaction with quality of 
care question asked in round 2 of the survey. Descriptive analysis of the study 
population was conducted and a logistic regression analysis was used to 
evaluate antibiotic utilization on reported patient satisfaction with quality of 
care. 
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Results: In 1996, 75% of patients with ARTls were overall very satisfied with 
the quality of care provided to them. The rate was also high when looking at 
antibiotic utilization against the different level of satisfaction whether antibiotics 
were used or not. The logistic regression model showed that before and after 
controlling for any variables that may influence our results, antibiotic utilization 
has no statistical significant on patients reported satisfaction with their quality 
of care. 
' Conclusion: The results of the study suggest that in this population the level 
of patient satisfaction with the quality of care provided is not influenced by 
whether antibiotics are prescribed or not. Health care systems and providers 
should not focus on antibiotic prescribing as a mean of patient satisfaction, but 
on the appropriate use of such antibiotics and the avoidance of unwanted 
effects. 
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Introduction: 
-
Studies that look at satisfaction are part of a larger area of research known as 
outcomes research, which is a multi-dimensional approach of evaluating the 
outcomes of the health care system, of which not only clinical outcomes are of 
interest, but also information about the patient functional outcomes, patient 
satisfaction, and cost-effectiveness of the health care provided.[1, 2] One of 
these dimensions that has attracted a great deal of interest in the last couple 
of years is,on studies that uses satisfaction as an indicator for the quality of 
care.[3] Studies that examine the patient perspective are considered an 
important method in the evaluation and assessment of the quality of the health 
care system.[4] 
Satisfaction shows the realities about care, as well as the expectations and 
preferences of the patient. Both expectations and preferences can be viewed 
as the determinants of satisfaction.[5] The expectation of patients have been 
linked to different level of satisfaction with the health care system, patients' 
tendency to sue the health care provider, compliance to the suggested 
therapy, the physician's decision for ordering different tests, and the ability to 
achieve the desired clinical effect. [6, 7] Patient satisfaction can be viewed as 
a performance evaluation of any health service.[8] Patients' satisfaction has 
been defined as "the reaction of the patient to the salient aspects of the 
context, process, and result of the service experience" [2, 9] 
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Satisfaction and other health care outcomes information are relevant to 
patients, the payers and to the providers.[10, 11] The consumers of the health 
care system are demanding a better service from providers and payers and 
decision makers are trying to follow their expectations,[12] by aiming to help 
patients achieve the best satisfying health outcome in the most efficient 
way.[7] So both the provider and the receiver of the health care service may 
be making decisions based on the level of satisfaction as measurable by 
outcome studies.[13] 
' 
The information gathered from such studies can be used in some of the 
following areas: to compare between different providers, examine at the 
provider performance over time, set priorities for projects that may improve 
quality, and determine the influence of changes in quality of care with changes 
in the healthcare delivery system.[14] 
Satisfaction studies have been conducted in many disease states and 
conditions, for example, studies have examined patient satisfaction in 
HIV/AIDS, diabetes, and cancer.[15-17] Information from such studies are 
usually gathered from a single item or multiple item questionnaires, where the 
multiple item questionnaires tend to be more reliable in capturing different 
levels of satisfaction.[2] However, the main problem with these kinds of studies 
is that high satisfaction has been reported utilizing many of them and there is a 
potential bias involved in the collection of such data.[18] 
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The influence of prescribing drugs on patient satisfaction, in general, has been 
shown in a study that explored whether patient expectations drive drug 
prescribing and if that has any effect on the level of satisfaction. The study 
showed that meeting the expectations of the patient is not associated with 
higher satisfaction.[19) 
Several satisfaction studies have been conducted in patients with acute 
nonpneumonic respiratory tract infections (ARTls). The objective of these 
studies was to explore the influence of both the prescribing of an antibiotic and 
the patients expectations on their satisfaction. One study showed that 65% of 
patients with respiratory infection expected an antibiotic, 63% received them, 
and 97% of the patients were satisfied with their visit.[20) No association was 
found between an antibiotic prescription and patient satisfaction. However, the 
strongest association with patient satisfaction was based on whether the 
physician spent sufficient amount of time explaining to the patient about his 
illness. 
A second study explored the influence of reducing antibiotic prescribing for 
uncomplicated acute bronchitis on patient satisfaction.[21) The study 
concluded that reducing antibiotic prescribing through educating both patients 
and clinicians was not associated with a reduction in the satisfaction of care. A 
third study has also concluded that in patients with upper respiratory tract 
infections, patients want to be diagnosed but their satisfaction with their 
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medical care depends on the personal interest and reassurance they receive 
from their provider. [22] 
The over prescribing of antibiotics in ARTls, that in many cases may be 
unnecessary, has been demonstrated in many studies.[23-25] This 
overutilization is not without the risk of getting antibiotic resistance and the 
high potential cost associated with such practice.[26-28] For that and for other 
reasons, it is important to study the influence of any factor that may lead to 
such a practice. 
The objective of this study was to explore the influence of prescribing 
antibiotics to patients with ARTls on their reported satisfaction with the 
provided quality of care. The hypothesis behind the study is that patients 
receiving antibiotics for ARTls are more likely to be satisfied with their reported 
quality of care than in patients not receiving them. 
The results of this study will be of a great value for both the providers and the 
payers, who are trying to please and retain patients in their plans and 
practices and, at the same time, lower their cost and avoid unnecessary use of 
medications. This study is unique compared to studies conducted in the past, 
because it attempted to study the patient satisfaction from a national dataset 
that allowed calculation of national estimates about satisfaction. 
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Methods: 
-
Data source: 
The source of data in this study was the 1996 Household Component (HC) of 
the Medical Expenditure Panel Survey (MEPS). MEPS is a national database 
that is cosponsored by the Agency of Healthcare Research and Quality 
(AHRQ), and the National Center of Health Statistics (NCHS). A couple of 
published studies have used the 1996 MEPS to examine the impact of 
different factors, such as managed care, health insurance and race on 
satisfaction. [29-31] 
The HC contains many files that are publicly available, and contains medical 
expenditure data at both the person and household level and, when weighted, 
provides nationally representative estimates of health care access, 
satisfaction, utilization, quality, expenditure, source of payments, and 
insurance coverage for the United States civilian non-institutionalized 
population.[32] Sampling for the HC is drawn from 10,500 household 
participants in the 1995 National Health Interview Survey (NHIS), conducted 
by NCHS. NHIS provides a nationally representative sample of the U.S. 
civilian non-institutionalized population, with oversampling of blacks and 
hispanics.[32] 
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The HC files that have been used in the analysis are the 1996 full year 
consolidated data and 1996 prescribed medicine event. The full year 
consolidated file contains one record for each of 22,601 persons and when 
weighted can be used to make national estimates of utilization and 
expenditures for calendar year 1996.[33] The prescribed medicine events file 
provides detailed information on 147,308 prescribed medicine events of 
household-reported prescribed medicines, and when weighted, can be used to 
make estimates of prescribed medicine utilization and expenditures for 
' 
calendar year 1996. In addition the prescribed medicine file contains 
household reported characteristics and medical conditions associated with 
prescribed medicine.[34] 
For the purpose of this analysis both files were merged. This allowed us to 
append personal characteristics such as demographic and health insurance 
coverage to each prescribed medicine record. Information about merging was 
derived from the data codebooks.[33, 34] The data were then transposed to 
make the unit of interest to be patients, instead of prescription events. 
Study population: 
The study population was (N=514) patients with ARTls, who answered the 
question about their satisfaction with the quality of care provided to them. 
ARTls were identified by the International Classification of Diseases, Ninth 
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.. n Clinical modification codes (ICD-9 codes), that were associated with Rev1s10 
ribed medicines. Each prescribed medication was associated with up to presc 
three ICD-9 codes. The prescribed medicines were reported by patients and 
were then confirmed from pharmacy records. The study only included 
prescriptions with one ICD-9 code to assure that the prescribed medicine of 
interest is for a particular ICD-9 code. Conditions included: acute 
nasopharyngitis (common cold), acute sinusitis, acute pharyngitis, acute 
tonsillitis, acute laryngitis and tracheitis, acute unspecified upper RTls, and 
acute bronchitis. 
Definition of variables: 
Dependent Variable (DV): 
The dependent variable of interest in this study was the reported patient 
satisfaction with their quality of care. Information about this variable was 
gathered from the satisfaction question only asked in the second round of the 
1996 MEPS and therefore the study population was limited to only this round. 
This variable was reported in four different satisfaction levels and, for the 
purpose of this study it was dichotomized to very satisfied and to some degree 
of dissatisfied. 
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Independent Variable (IV): 
The main variable of interest was whether or not an oral antibiotic was utilized 
tor any of the ARTls conditions explored in the study, and if that had any effect 
on patients' satisfaction level. 
Other variables: 
Demographic and socioeconomic variables were also examined for any 
' difference in the satisfaction level and to determine whether they may be 
potential confounders. Variables included: sex, race, age, marital status, 
census region, poverty line, type of health insurance, the number of 
prescriptions and refills in 1996, and total health care expenditure in 1996. 
The last two variables (number of prescriptions and total expenditure) were 
used in the analysis to try to capture both the burden of other co-morbidities 
and extent of overall health care utilization on the satisfaction level. The 
information about other conditions were not available in the data used for this 
study. The information about other co-morbidities can only be gathered for the 
medical condition file. However, the problem with that is that not all records in 
the medication file have a match in the prescription event file used in the 
study. 
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Statistical analysis: 
This study utilizes both descriptive and analytical techniques in its analysis. A 
chi-square test was carried out to examine the difference between the various 
independent variables on the patient satisfaction level, with p-values reported. 
The level of significant used for a p-value was alpha=0.05. 
Logistic regression was used to determine the relative risk of the utilization of 
antibiotics on the level of patient reported satisfaction with their quality of care. 
The final logistic regression model was run while controlling for confounders. 
Odds ratios and the 95% confidence interval were used. 
Several analytical techniques have been used to build the final logistic 
regression model. First, variables were dichotomized and dummy variables 
created for the following variables: age, census region, health insurance, 
poverty line, number of prescriptions in 1996 and the total health care 
expenditure in 1996. Second, univariate logistic regression was used to 
evaluate the relative contribution of each independent variable on predicting 
patient satisfaction. Third, we examined possible interaction terms between 
the main independent variable and other variables. Three, two, and one term 
interactions were done and the presence of an interaction was based on the 
result of log likelihood ratios in the chunk test. 
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The fourth technique used was testing for multi-collinearity and that was 
performed to examine highly correlated variables and, if necessary, remove 
any variable from the model. Finally, testing for potential confounders that may 
influence our final model was carried out by comparing the B (coefficient) of 
the primary independent variable (patient satisfaction) of the full model to each 
reduced model (i.e., a model missing on variable). 
All statistical analysis were carried out using SAS version 8.1 (SAS Institute, 
Cary, North Carolina) and SUDAAN software package (Research Triangle 
Institute, Research Triangle Park, North Carolina), both licensed to the 
University of Rhode Island. The results of the study have been weighted to 
give 1996 national estimates of the influence of antibiotics utilization on the 
reported patient satisfaction with their quality of care in ARTls. Many 
references for SAS and SUDAAN programming, methodology, and interpreting 
results were used.[35-39] 
Results: 
The study population of unweighted and weighted data of 514 patients with 
ARTls is shown in Table 1. It demonstrates the high rate of satisfaction of the 
study population regardless of any medication use, which was around 75% 
versus 25% for all the other levels of satisfaction. Satisfaction, which was 
dichotomized into complete satisfaction (i.e., very satisfied) or to some degree 
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of dissatisfaction, was also reported. The table also shows the rate of antibiotic 
use in patients in the study population, which was around 63%. 
A simple cross-tabulation, without controlling for any other variables, was 
conducted between the satisfaction level and antibiotic use as shown in Table 
2, in which patient's satisfaction is very high whether or not antibiotics were 
used. It was around 75% for both groups. 
' The demographic characteristics of the study population are presented in 
Table 3, for both the weighted and unweighted data, which shows that 85% of 
the patients are white Americans and 57% are female. Children 17 years old 
and younger accounted for 45% of our study population and that was probably 
why the majority of patients in the study were not married (71 %). 
Table 4 presents the socioeconomic characteristics and shows that 73% of 
patients were covered by private health insurance. The table also shows the 
patients different income level, in which 63% of them have middle to high 
income. It also shows the number of prescriptions and refills in 1996 and the 
total health care expenditure in 1996. 
The unweighted chi-square analysis demonstrated that when examining 
patient satisfaction, the variables that show a significant differences on the 
level of satisfaction were race and total health care expenditure in 1996 (Table 
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When the data were weighted using SUDAAN, none of the variables 5). 
d a significant difference on the level of satisfaction. The table shows showe 
that in all of the variables, patients were more likely to be very satisfied, rather 
than having some degree of dissatisfaction. 
A chi-square analysis was also conducted between the main independent 
variable (antibiotic utilization) with all the other independent variables, in order 
to help verify any potential confounder. The variables that showed a significant 
' difference were race, the type of health insurance coverage and poverty 
status. However, when the data was weighted using SUDAAN, the variables 
that showed a significant difference were only race and the type health 
insurance coverage. 
From the results of the conducted chi-square tests, we concluded that the only 
potential confounder for the unweighted data was race, since it showed a 
significant difference when looking at both antibiotic utilization and the 
satisfaction variables. However, no potential confounders were found when 
the data was weighted with SUDAAN. 
The univariate logistic models showed that race and the total number of 
prescriptions in 1996 was the only variables which had an independent effect 
on the level of satisfaction. The interaction assessment conducted concluded 
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that no interaction terms exist between the variables. The analysis also 
showed that no highly correlated variables exist. 
The final logistic regression model presented in Table 6 indicated that, before 
controlling for other variables, antibiotics effect on the level of patient 
satisfaction with their quality of care is not significant with an odds ratio (OR) = 
and a 95% confidence interval (Cl) = 0.63 - 1.63 and a p-value of 0.9707. 
Similar results were found, when trying to control for race, total healthcare 
' 
expenditure in 1996 and the total number of prescription in 1996. 
Discussion: 
The results of the study demonstrate that overall satisfaction with quality of 
care in patients with ARTls in 1996 were very high, which was around 75% of 
patients. The results also showed that patients with different demographics 
and socioeconomic background were very satisfied, regardless of any 
antibiotic use. 
Our study suggested that the utilization of antibiotics in patients with ARTls is 
not considered to be an important factor that may influence patient satisfaction 
with their quality of care. Results from our logistic regression analysis 
indicated that no changes in the level of satisfaction were found whether 
antibiotic were used or not. Findings were consistent with many of the studies 
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that examined the influence of medication utilization on patient satisfaction in 
general and in ARTls in particular.[19-22] 
A number of potential limitations are associated with this study. First, the study 
is a cross-sectional, which prevented examination of the change in the 
reported patient satisfaction over time. Second, the satisfaction level was very 
high in all the variables used in the study, which may suggest the presence of 
a bias introduced by the survey administrators (i.e., interviewer bias) or by the 
instrument used in the study. Third, the satisfaction question in the study was 
asked based on the satisfaction with the quality of care, reported by patients or 
by their parents, and was not specifically based on antibiotics utilization. 
Despite these limitations, the methodology used in the study was able to utilize 
a national dataset to capture the influence of antibiotic utilization on the 
reported satisfaction on a national level. The results of the study may be very 
helpful for physicians and providers of the health care system, who are trying 
to use antibiotics appropriately and at the same time to satisfy their patients. 
The results illustrated that they should not worry about patient satisfaction 
when treating these illnesses and should instead concentrate on the 
appropriate use of antibiotics in their patients. 
This research points out the need tor similar studies that will take into account 
the problems and limitations associated with studies measuring patient 
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· of their health care. More standardized and disease specific perceptions 
instruments should be used, only after being tested for both validity and 
reliability, which in many cases has not been done.[18, 40] That will help 
avoid, or at least minimize the biases introduced, and will also help interpret 
the study findings accurately.[18] 
Researchers and people involved in the design of a future national database, 
whether it is MEPS or any other, should pay more attention and try to 
introduce new questions that will capture the influence of the medication use 
on patient satisfaction. That will help provide national estimates, instead of 
using small studies that in many cases can not be generalizable and are of 
limited use to health care decision makers. 
CONCLUSION: 
The results of the study suggest that the level of patients' satisfaction with the 
quality of care provided is not influenced by whether antibiotics are prescribed 
or not. Health care systems and providers should not be concerned about 
losing patients to other organizations due to antibiotic prescribing patterns, or 
of making their patients less satisfied if not prescribed an antibiotic. The 
concentration of such providers should be on the appropriate use of such 
antibiotics and the avoidance of any unwanted effect (e.g., antibiotic 
re · t · sis ance). This may be accomplished through an educational program 
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tocusing on clinicians and on patients, and by spending more time explaining 
to patients about their condition and the therapeutic options available, if any. 
' 
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T ble 2.1 Response to a satisfaction with quality of care question in a study 
8 ulation of atients with ARTls*, wei hted to enerate national estimates. 
Satisfaction with Quality of Care 
Very satisfied 
Somewhat satisfied 
Not too satisfied 
Not at all satisfied 
Satisfaction with Quality of Care 
Very satisfied 
Some'degree of dissatisfaction 
Antibiotic received 
No 
Yes 
*ART/s=Acute Respiratory Tract Infections 
Unweighted 
(N=514) 
N (%) 
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388 (75.49) 
107 (20.82) 
16 (3.11) 
5 (0.58) 
388 (75.49) 
126 (24.51) 
199 (38.72) 
315 (61.28) 
Weighted (in millions) 
(N=6.01) 
N (%) 
4.53 (75.39) 
1.26 (20.95) 
0.185 (3.08) 
0.034 (0.57) 
4.53 (75.39) 
1.47 (24.6) 
2.24 (37.26) 
3.77 (62.74) 
Table 2.2 Percentag~ ~f ~ati~~t ~ith ARTls*, answering a satisfaction with quality of 
care uestion and ant1b1ot1c ut1hzat1on status. 
Satisfaction 
Verv Satisfy Some degree of Dissatisfaction 
Antibiotic utilization 
Yes 
No 
Antibiotic users 
No antibiotic used 
47.3% 
28.1% 
75.5% 
75.3% 
*ART/s=Acute Respiratory Tract Infections 
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15.4% 
9.2% 
20.8% 
24.7% 
Table 2.3 Demographic ~harat~teris1 ticst_of tthe study population of patients with ARTls*, wei hted to obtain na 1ona es 1ma es. 
Unweighted Weighted (in millions) 
(N=514) (N=6.01) 
~riables N (%) N (%) 
sex 212(41.25) 2.58(42.97) Male 
Female 302 (58.75) 3.43 (57.03) 
Race 
White 425 (82.68) 5.11 (85.03) 
Non-white 89 (17.32) 0.90 (14.97) 
Age 
Children (0-17) 257 (50) 2.75 (45.87) 
18-44'yrs 149 (28.99) 1.96 (32.63) 
45-90 yrs 108 (21.01) 1.29 (21.50) 
Marital Status 
Married 144 (28.02) 1.69 (28.16) 
Not married 370 (71.98) 4.32 (71.84) 
Census Region 
Northeast 97 (18.87) 1.09 (18.27) 
Midwest 108 (21.01) 1.38 (22.94) 
South 187 (36.38) 2.16 (35.91) 
West 122 (23.74) 1.37 (22.87) 
*ART/s=Acute Respiratory Tract Infections 
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1 2 4 
socioeconomic characteristics of the study population of patients with 
Ta~~* "wei hted to obtain national estimates. 
AR 5 ' Unweighted Weighted (in millions) 
(N=514) (N=6.01) 
Variables N (%) N (%) 
Income (poverty line) 
Negative or poor 
Near poor 
Low income 
Middle income 
High income 
Health insurance 
Any private 
Public only 
Uninsured 
' 
118 (22.96) 
24 (4.67) 
77 (14.98) 
163 (31 .71) 
132 (25.68) 
347 (67.51) 
131 (25.49) 
36 (7) 
Number of prescription and refills in 1996** 
1-2 122 (23.74) 
3-4 120 (23.35) 
5-12 174 (33.85) 
>13 98(19.07) 
Total healthcare expenditure in 1996** 
$1-$179 90 (17.51) 
$180-$524 163 (31.71) 
$525-$1659 147 (28.60) 
$1660-$427086 114 (22.18) 
*ART/s=Acute Respiratory Tract Infections 
1.03 (17.13) 
0.19 (3.25) 
0.97 (16.20) 
2.03 (33.80) 
1. 78 (29.62) 
4.42 (73.56) 
1.15 (19.26) 
0.43 (7.18) 
1.41 (23.54) 
1.30 (21.62) 
2.15 (35.75) 
1.14 (19.09) 
0.93 (15.48) 
1.82 (30.30) 
1.94 (32.39) 
1.31 (21.82) 
**No zero values for these variables since the data is a prescribed medication data. 
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1 2 5 Bivariate analysis between the satisfaction with the quality of care and all Tab ~he~ variables in atients with ARTls*, wei hted to obtain national estimates. 
the 0 Satisfaction 
very Some degree of 
YiJriables Satisfy(%) Dissatisfaction (%) 
Sex 
Race 
Age 
Male 
Female 
White 
Non-white 
Children (0-17) 
18-44 yrs 
45-90 yrs 
Marital Status 
Married 
Not married 
Census Region 
Northeast 
Midwest 
South 
West 
Income (poverty line) 
Negative or poor 
Near poor 
Low income 
Middle income 
High income 
Health insurance 
31.32 
44.16 
64.40 
11.09 
37.16 
22.57 
15.76 
21 .60 
53.89 
13.81 
15.37 
29.38 
16.93 
15.95 
3.50 
12.06 
25.10 
18.87 
9.92 
14.59 
18.29 
6.23 
12.84 
6.42 
5.25 
6.42 
18.09 
5.06 
5.64 
7 
6.81 
7 
1.17 
2.92 
6.61 
6.81 
Any private 52.53 14.98 
Public only 18.29 7.20 
Uninsured 4.67 2.33 
Number of prescription and refills in 1996 
1-2 17.90 5.84 
3-4 16.34 7 
5-12 25.10 8.75 
>13 16.15 2.92 
Total healthcare expenditure in 1996 
$1-$179 11 .67 
$180-$524 22.76 
$525-$1659 23. 15 
$1660-$427086 17.90 
5.84 
8.95 
5.45 
4.28 
P-value** 
0.8401 
0.0058 
0.7212 
0.5995 
0.2086 
0.3072 
0.1728 
0.0853 
0.0287 
"!;e lev:_J of significa~t used is p-value of O. 05 
.. 'if:ls-A~ute Respiratory Tract Infections 
e weighted bivariate analysis showed no significant difference for any variable. 
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Table 2.6 Final logi~tic r~gres~ion m?del f~r the effect. of antibiotic utilization on 
ported patient sat1sfact1on with their quality of care in a study population of ARTls*, 
:ei hted to obtain national estimates. 
Antibiotic utilization** 
Without controlling for any variables 
Controlling for health care utilization*** 
OR (95% Cl) 
1.01 (0.63 - 1.63) 
0.97 (059 - 1.59) 
Controlling for health care utilization & race 0.93 (0.56 - 1.53) 
Note: OR=odd ratios, 95% Cl= 95% confidence interval 
~ls=Acute Respiratory Tract Infections 
**No variable have shown to be a potential confounder. 
P-value 
0.9707 
0.9066 
0.7669 
***controlling fdr total health care expenditure and total number of prescriptions in 1996. 
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The Influence of Drug Copayment on Antibiotic Utilization in Acute 
Respiratory Tract Infections 
Abstract 
Background: Identifying the influence of prescription drug copayments on the 
decision to obtain or prescribe an antibiotic is essential and may play an 
important role in the health care decision making process due to the 
associated ~ost and the potential for misutilization. 
Objectives: The main objective of this study was to explore the effect of the 
drug copayment of the prescribing of antibiotics in acute respiratory tract 
infections (ARTls) and if that may increase or decrease the inappropriate use 
of such antibiotics. The study also tried to estimate the total savings in dollars 
to both the insurers and patients when paying for these unnecessary 
medications prescribed for different ARTls. 
Methods: A retrospective study of (N=1635) prescription events associated 
with different ARTls was identified from the 1996 Medical Expenditure Panel 
Survey (MEPS). Antibiotic use was determined by selecting oral antibiotics 
and the associated source of payment (e.g., copayments) with each 
prescription was also identified. A logistic regression model was developed to 
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evaluate prescription drug copayment effect on prescribing an antibiotic. The 
total cost that may have been spent on these antibiotics was also estimated. 
Results: In 1996, the total spending on potentially inappropriate antibiotics for 
different ARTls was around $394 million, which could be saved for both the 
patient when paying copayments and to the health care insurer. The results of 
the logistic regression analysis concluded that medication copayments do not 
have a significant effect on the utilization of antibiotics in these conditions, with 
' 
an odds ratio (OR) = 1.03 and a 95% confidence interval (Cl) = 0.99 to 1.08 
and a p-value of 0.1269. 
Conclusion: The results of the study indicate that prescribing antibiotics for 
ARTls, which may be unnecessary, are associated with high medication costs 
and could be avoided. This is especially true with the limited resources 
available and with the rapid increase in the health care spending. The study 
also showed that the likelihood of being prescribed an antibiotic is not affected 
by the level of drug copayment. However, more research is needed to 
examine the effect of the different copayment tier systems introduced in the 
last couple of years on the utilization of these drugs. 
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Introduction: 
--- . 
Recently, the increase in the cost of health care has reached alarming levels. 
In 2001, health care cost was around $1.4 trillion, which accounted for 14% of 
the total United States gross domestic product (GDP), and prescription drugs 
accounted for about 10% of the total health care cost. The numbers are 
expected to rise to about $2.8 trillion in 2011, which will account for 17% of the 
estimated total GDP. The figures for prescription drugs will reach 14.7% and 
the total spending on pharmaceuticals will be 2.5% of the total GDP.[1] 
The above figures have led many people interested in this area to focus and 
conduct research to identify methods that may lead to the lowering of total 
spending on health care in general and on prescription drugs in particular. 
Their research is aimed at minimizing spending without affecting the level of 
patient satisfaction and other health care outcomes.[2-4] 
Techniques that address prescription drug utilization were mainly developed 
by Pharmacy Benefits Management organizations (PBMs). These 
organizations use many tools and techniques to accomplish their goal of 
lowering the cost they incur for medications. The techniques include disease 
state management, formulary management, drug utilization reviews, delivery 
systems (e.g., mail order, retail), and by consumer sharing (e.g., 
copayments).[2, 5-7] 
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This study focused on one of these cost sharing techniques, drug copayment. 
Many copayment strategies have been initiated by public and private 
organizations to lower their share of prescription drug costs. For example, a 
survey showed that many employers intend to increase the cost sharing in 
their health care benefit structure, rather than eliminating drug coverage.[8] 
Many states are also limiting or restricting eligibility in their drug coverage 
programs.[9] 
' Copayment is defined as a fixed amount of dollars that a patient must pay per 
prescription.[1 O] Health plans may use different tier system when applying 
copayments. In 2000, 49% of covered workers were in plans of two-tiered 
structure. The rate was down to 37% in 2001.[11] The reason behind using 
two tiers was to differentiate between generic and brand drugs and to 
encourage patients to use generic drugs at a lower copayment level.[1 O] 
However, generic drug dispensing rate of 42% has not change from 1996 to 
2000, with a decline in the annual sales of generic prescriptions from 20.5% in 
1996 to around 17.8% in the year 2000.[12] 
In order to increase the use of generics, different health care plans are now 
moving to simple multiple tier systems (e.g., three tier) and to more complex 
systems (e.g., four and five tiers) and even to coinsurance, where patient pay 
a percentage of the cost of the drug.[3, 1 O, 13, 14] Multitiered copayments 
were created to make a balance between what health plans need to control 
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pharmaceutical costs and their need to avoid public criticisms for limiting 
access to drugs.[15] 
Research conducted in the past about cost sharing has suggested that 
overutilization may be decreased when patients are required to pay part of the 
expenses they incur.[16-20] One report that surveyed about 150 health plans 
with different cost sharing plans concluded that a direct relationship exists 
between the decrease in drug utilization with the increase in cost sharing. The 
' 
respondents recommended a 5%-10% cost sharing to have an effect without 
having a negative outcome on the use of essential drugs.[21] 
Another study indicated that an increase in drug copayments from $5 to $7.50 
was associated with 12.3% reduction in drug spending in health maintenance 
organizations. [22] Also, a study that examined the effect of three tier copay 
systems concluded that these techniques can control drug costs.[23] 
Information regarding the effect of drug cost sharing and copayments on the 
utilization of essential drugs are conflicting. One study showed that increased 
cost-sharing for prescription drugs in elderly and welfare recipients was 
associated with a decrease in the use of essential drugs and with higher rate 
of emergency department visits.[24] One survey suggested that higher out of 
pocket costs may causes a high non-compliance among users of prescription 
drugs.[25] 
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On the other hand, a study demonstrated that compliance rates with chronic 
disease medications in the period of 6 months after a copay increase of $10 to 
$15 for brand drugs was not reduced when comparing the study group to a 
control group.[26] Other studies have also shown no effect on the use of 
essential drugs when copayments are increased in certain disease states 
(e.g., cardiac medications).[27, 28] 
To date, no study has examined the influence of drug copayments on the 
' prescribing and/or purchasing of antibiotics in Acute Respiratory Tract 
Infections (ARTls), except for one study that only examined the effect of 
copayment on the purchasing of drugs for children in infections in general and 
that was not limited to ARTls. [29] 
The importance of exploring these issues is crucial, especially in conditions 
like ARTls where there are, in many cases, not only an overutilization and 
inappropriate use of antibiotic, but unnecessary costs resulting from both the 
cost of the drug and from the side effects associated with its use (e.g., 
antibiotic resistance).[30-32] Patients financially responsible for low or no 
copayments may provide more incentive to fill the prescription.[33, 34] 
ARTls include conditions where antibiotics are generally considered to be 
inappropriate such as in acute nasopharyngitis (common cold), acute 
unspecified upper respiratory tract infections, acute bronchitis, and acute 
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laryngitis and tracheitis.[35, 36] In other ARTls conditions, such as acute 
pharyngitis and acute sinusitis, antibiotics are in many cases not 
recommended, but may be beneficial in some patients.[35] 
The objective of this study was to explore the effect of the drug copayment on 
the prescribing of antibiotics in ARTls and if there is an increase or decrease 
the inappropriate use of such antibiotics. One hypothesis was that patients 
responsible for no copayments were more likely to receive an antibiotic for one 
' 
of the ARTls conditions compared to patient with copayments. The study also 
tried to estimate the total savings in dollars to both the insurers and patients 
when paying for these unnecessary medications in the different ARTls. 
69 
Methods: 
--
Data source: 
The 1996 Household Component (HC) of the Medical Expenditure Panel 
survey (MEPS) provided the data for this study. MEPS is a national publicly 
available database that is cosponsored by the Agency for Healthcare 
Research and Quality (AHRQ), and the National Center of Health Statistics 
(NCHS). The HC contains many files that provide medical expenditure data at 
' both the person and household level and, when weighted, provide nationally 
representative estimates of health care access, satisfaction, utilization, quality, 
expenditure, source of payments, and insurance coverage for the United 
States civilian non-institutionalized population.[37) 
Files used in the analysis were for the 1996 full year consolidated data and 
1996 prescribed medicine event. The full year consolidated file contains one 
record for each of 22,601 persons and when weighted, can be used to make 
national estimates of utilization and expenditures for calendar year 1996.[38] 
The prescribed medicine events file provides detailed information on 147,308 
prescribed medicine events of household-reported prescribed medicines, and 
when weighted, can be used to make estimates of prescribed medicine 
utilization and expenditures for calendar year 1996. In addition the prescribed 
medicine file contains household reported characteristics and medical 
conditions associated with prescribed medicine.[39) 
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For the purpose of this analysis both files were merged. This allowed us to 
append personal characteristics, such as demographic and health insurance 
coverage, to each prescribed medicine record. Information about merging was 
derived from the data codebooks.[38, 39] 
study population: 
The study population was for 1635 prescription events associated with one of 
the following. ARTls: acute nasopharyngitis (common cold), acute sinusitis, 
acute pharyngitis, acute tonsillitis, acute laryngitis and tracheitis, acute 
unspecified upper RTls, and acute bronchitis. These conditions were identified 
from 1996 MEPS by using the International Classification of Diseases, Ninth 
Revision Clinical modification codes (ICD-9 codes). 
Exclusion criteria: 
Since each prescribed medication was associated with up to three ICD-9 
codes, any event with more than one ICD-9 code was excluded to assure that 
the prescribed medicine of interest was for a particular ICD-9. The study also 
excluded any prescription event where the patient or any family member paid 
for the prescription in full, since the study was only examining the influence of 
copayments. 
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Definition of variables: 
Dependent Variable (DV): 
The dependent variable of interest was defined as having been prescribed an 
antibiotic or not, and only oral antibiotics were included in the analysis. 
Independent Variable (IV): 
' Copayment was the independent variable of interest in this study. Information 
about this variable was constructed from prescription drugs payment 
information available in the data. Copayment was examined both continuously 
and categorically. In the latter case, the variable was designated as no 
copayment or copayment. Two categories were created because many of the 
copayments in the study population were between $5 and $10, and it was 
difficult to determine more break points. 
Other variables: 
Demographic and socioeconomic variables were also examined for any 
association with antibiotic utilization and to determine whether may confound 
the effect of copayment on the utilization of antibiotics in ARTls. Variables 
included: sex (male or female), race (white or non-white), age (less than 17 
years old or older than 18), census region (northeast, west, south, or 
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midwest), poverty status (poor to low income or moderate to high income), 
type of health insurance (any private, any public, or no insurance). 
Statistical analysis: 
A simple descriptive analysis of the study population was conducted, and 
included examining the different demographic and socioeconomics 
characteristics in this population. 
The analysis also estimated the total savings to patients and to public or 
private drug coverage insurers, if antibiotics have been avoided in the different 
conditions of ARTls. The unweighted total savings were calculated by 
summing up all antibiotics payments, both by patients and by health insurers, 
and then the total number of antibiotic prescriptions and the total dollar value 
were weighted using SUDAAN to obtain national estimates. 
Other analysis: 
A bivariate analysis was conducted between the different study variables with 
antibiotic utilization, and a chi-square test was carried with p-values reported. 
The level of significant used for a p-value was alpha=0.05. 
logistic regression analysis was utilized to evaluate prescription drug 
copayment effect on prescribing an antibiotic. The final logistic regression 
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model was run while controlling for confounders. Odds ratios and the 95% 
confidence interval were reported . 
Several analytical techniques were used to build the final logistic regression 
model. First, variables were dichotomized and dummy variables created for 
the following variables: age, census region, health insurance, income level. 
Second, univariate logistic regression was used to evaluate the relative 
contribution of each independent variable on predicting antibiotic utilization. 
' Third, testing for multi-collinearity was performed to examine highly correlated 
variables and, if necessary, remove any variable from the model. Finally, 
testing for potential confounders that may influence our final model was 
carried out by comparing the B (coefficient) of the primary independent 
variable (antibiotic utilization) of the full model to each reduced model (i.e., a 
model missing one variable). 
All statistical analysis was performed using SAS version 8.1 (SAS Institute, 
Cary, North Carolina) and SUDAAN software package (Research Triangle 
Institute, Research Triangle Park, North Carolina), both licensed to the 
University of Rhode Island. The results of the study were weighted to give 
1996 national estimates of the influence of antibiotics utilization on the 
reported patient satisfaction with their quality of care in ARTls. Many 
references for SAS and SUDAAN programming, methodology, and interpreting 
results were used.[40-44] 
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Results: 
-
Information about the study population including demographic and 
socioeconomic characteristics are presented in Table 1, which shows both the 
weighted and unweighted data for (N=1635) medication events with different 
types of ARTls. The table also highlights that in 1996 around 73% of 
medication events for ARTls were associated with a copayment. The rate of 
antibiotic prescribing for these conditions was 49%. 
' The analysis also estimated the total direct cost in dollars that can theoretically 
be saved by eliminating unnecessary antibiotic use in ARTls (Table 2) and it 
shows that in 1996, the total savings to patients from copayments in conditions 
like common cold, acute tonsillitis, acute laryngitis and tracheitis, acute 
unspecified upper RTls, and acute bronchitis, were antibiotics are always 
considered unnecessary, was around $71 million. Potential savings for 
different drug coverage programs were estimated at $243 million. 
Table 2 also shows that in 1996, the total saving to patients from copayments 
in conditions like acute sinusitis and acute pharyngitis, where antibiotics may 
be used but in many cases are considered unnecessary was around $17 
million and $63 million would accrue to the benefit of providers and payers of 
different drug coverage programs. The total cost that could have been saved 
in 1996 from inappropriate antibiotic prescribing in ARTls was approximately 
$394 million. 
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The results of the weighted cross tabulation between copayment and antibiotic 
utilization against the different study variables are presented in Table 3, which 
also shows the results of the chi-square test. The variables that demonstrated 
a significant effect (p-value less than 0.05) with drug copayment were health 
insurance, income level, age and race. Variables with a significant effect on 
antibiotic utilization were health insurance, income level and race. 
The results from the different techniques for logistic regression showed no 
' 
correlation between variables in the study population. Univariate logistic 
regression showed that the variables that have an independent effect on 
antibiotic utilization were only health insurance, income and race. Table 4, 
present information regarding the results of confounders assessment, in which 
income level, health insurance and race were potential confounders that need 
to be controlled for in the final logistic model. 
The results of the final model showed that before controlling for the potential 
confounder, copayments had a significant effect on antibiotic utilization in 
different events of ARTls with an odds ratio (OR)=1.06 and a 95% confidence 
interval of 1.01 to 1.11 and a p-value of 0.0171. However, after controlling for 
potential confounders (i.e., health insurance, income and race) the effect of 
copayment on the utilization of antibiotics disappeared, with an odds ratio 
(OR)=1.03 and a 95% confidence interval (Cl) = 0.99 to 1.08 and a p-value of 
0.1269. 
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Discussion: 
--
The findings from this study suggest that in 1996, patients or a family member 
paid a copayment for antibiotics prescribed for different ARTls in around 66% 
of events. The study also showed that the effect of copayment level on the 
utilization of antibiotics in these conditions disappeared after controlling for 
potential confounders. 
' The reason that in 1996 drug copayments has no effect on the utilization of 
antibiotics in ARTls may be due to 1) patients may have a perception that they 
need antibiotics regardless of copayment level, and 2) copayment levels were 
low, in many cases less than $10 per prescription. 
This study is the first that has used a national dataset that allow the calculation 
of national estimates of the effect of drug copayment on antibiotic use in 
ARTls. The study also was able to calculate a national estimate of the direct 
cost in dollars that can be saved by both the patient and the prescription drug 
provider when these drugs are avoided, which was around $394 million in 
1996. This figure was lower than the expenditure reported for 1998, which was 
around $726 million, suggesting an increase in the spending on antibiotics 
associated with treating these conditions from 1996 to 1998. [30) 
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A number of potential limitations are associated with this study. First, the data 
used in the analysis does not provide information about the different benefits 
and copayment tier systems associated with each prescription drug plan. 
second, the study is cross-sectional in nature and may prevent analysts from 
capturing the influence of any change in the copayment tier system on 
antibiotic utilization over time. Finally, the data does not provide information 
regarding the causative agent, whether it is viral or bacterial, and also does 
not provide a history of other antibiotic use. 
Despite these limitations the study was able to show results that will assist 
policy and decision makers, both in the government and the private sector, 
who are responsible for designing the different copayment tier systems. It also 
illustrated that without the proper management of these conditions, significant 
levels of waste in the health care system can occur. This is of particular 
concern especially with the rapid increase in the cost of health care system 
with limited and scarce resources. 
Future research should focus on factors that may change the way ARTls are 
being managed. This research might include examination of a large national 
data (e.g., MEPS) to determine what level of copayment will change patient 
behaviors toward receiving antibiotics.[45] Other research might examine 
recently released MEPS data and compare it to the results of this study, 
knowing that many tier systems have changed since 1996 and newer systems 
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of cost containment have been introduced.[2, 1 O] It would also be helpful to 
estimate the overall cost associated with treating these conditions, and not 
concentrate only on the direct cost of medications. 
The copayment tier system available for prescription drugs is expected to 
evolve in the future to a newer system that is based on the overall benefits 
gained and risks avoided from medications both in terms of clinical and 
economic outcome.[46] 
Conclusion: 
The results of the study indicate that prescribing antibiotics for ARTls which 
may be unnecessary are associated with high medication cost that should be 
avoided especially with the limited resources available and with the rapid 
increases in the health care spending. The study also demonstrated that the 
likelihood of being prescribed an antibiotic is not affected by drug copayment. 
However, more research is needed to examine the effect on the different 
copayment tier systems introduced in the last couple of years on the utilization 
of these drugs. 
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Table 3.1 Study popul_at~on of. ARTls* eve~ts s_howing . the demographic and 
socioeconomic characteristics, we1 hted to obtain national estimates. 
Unweighted Weighted** 
(N=1635) (N=19.2 million) 
~riables (%) (%) 
Drug Copayment: 
No copayment 33.3 26.7 
Copayment 66.7 73.3 
Antibiotic utilization: 
No 52.8 51.5 
Yes 47.2 48.5 
Health insurance: 
Any private 69.1 76.1 
Any public' 29.9 22.9 
Uninsured 1.1 1.04 
Income level: 
Poor to low income 45.7 38 
Moderate to high income 54.3 62 
Gender: 
Male 42.6 44.3 
Female 57.4 55.7 
Race: 
White 82.9 84.8 
Non-white 17.1 16.2 
Age: 
Less than 17 50 45.3 
18 and more 50 54.7 
Region: 
Northeast 18.1 18.7 
Midwest 23 25.2 
South 37.9 36.4 
West 21 19.7 
*ART/s - Acute Respiratory Tract Infections 
**In millions 
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Table 3.2 Total cost sa~ings. per year to insu~er and yatient, if antibiotics were 
avoided in different ARTls , we1 hted to make national estimates. 
~ariables 
Unweighted 
(N=1635) 
($) 
When antibiotics are alwavs considered unnecessarv:** 
Total amount paid 
By patient or pay family 
By provider 
5,392 
20,771 
Weighted** 
(N=19.2 million) 
($) 
70,950,958 
242,854,627 
When antibiotics may be used but it many cases is considered unnecessarv:t 
Total amount paid 
By patient or pay family 
By provider 
For all ARTls: 
Total amount paid 
By patient or pay family 
By provider 
Total saving per year 
*ARTls =Acute Respiratory Tract Infections 
1,207 
5,022 
6,599 
25,793 
32,392 
17,098,202 
62,654,462 
88,049, 161 
305, 509, 089 
393,558,250 
•• Includes: acute nasopharyngitis (common cold), acute tonsillitis, acute laryngitis and tracheitis, acute 
unspecified upper RT/s, and acute bronchitis. 
t Includes: acute sinusitis and acute pharyngitis. 
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T ble 3.3 Drug copayments and antibiotic use stratified by health insurance, income le~el, ender, race, a e and census re ion*, wei hted to make national estimates. 
Drug Copayment** Antibiotic use+ 
~riables Yes(%) No(%) Yes(%) No(%) 
Health insurance: 
66.7 9.4 40.1 36 Any private 
Any public 5.79 17.12 8.13 14.8 
Uninsured 0.8 0.25 0.33 0.7 
Income level: 
Poor to low income 18.2 19.8 15 23 
Moderate to high income 55 7 33.6 28.4 
Gender: 
Male 33.6 10.7 22 22.3 
Female 39.7 16 26.6 29.1 
Race: 
White 64.6 20.2 43 41.8 
Non-white 8.7 6.6 5.6 9.6 
Age: 
Less than 17 27.4 18 23.4 22 
18 and more 45.8 8.9 25.2 29.4 
Region: 
Northeast 14.6 4 9.7 9 
Midwest 20.1 5 12.3 13 
South 26.3 10.1 18 18.3 
West 12.1 7.6 8.6 19.7 
*ART/s =Acute Respiratory Tract Infections 
Note: The level of significant used in the analysis was P-value of less than 0.05 
**The variables that showed significant different were heath insurance, race, age, and income level. 
:tThe variables that showed significant different were health insurance, race and income level. 
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Table 3.4 B (coefficient) of the primary independent variable (Copayment) for the full 
model, and the different models that are missin one variable. 
~riables {!, P-value 
Full model 0.04 0.7861 
Full - health insurance 0.22* 0.1348 
Full-Age 0.06 0.7131 
Full - Income level 0.13* 0.3915 
Full-gender 0.04 0.8010 
Full- Race 0.07* 0.6433 
Full - Region ' 0.06 0.7029 
*Potential confounders are health insurance, income level, and race. 
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Table 3.5 Results of t~e. final logistic regression ~hewing the odds of being prescribed 
antibiotics when exam1nin dru co a ments, we1 hted to make national estimates. 
Prescription drug copayment 
Before controlling for confounders 
Controlling for potential confounders 
OR (95% Cl) 
1. 06 (1.01-1. 11) 
1.03 (0.99-1.08) 
Note: OR=odd ratios, 95% CJ= 95% confidence interval 
"*POfential confounders were heath insurance, race, and income level. 
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P- value 
0.0171 
0.1269 
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Appendix A. Background and review of the problem: 
Respiratory tract infections (RTls) are considered to be the leading cause of 
prescribing antibiotics in community practice, counting for 75% of prescribed 
antibiotics. [1] These infections can be divided, based on the location of the 
infection, into lower respiratory tract infections (LRTls) such as pneumonia and 
bronchitis, and to upper respiratory tract infections (URTls) which includes 
rhinitis (common cold), sinusitis, pharyngitis (sore throat), and laryngitis.[1, 2] 
LRTls are considered to be one of the main reasons for morbidity and 
mortality, and for the increased health care utilization due to infections. It is 
estimated that 3.8 million deaths occurred in 1998 worldwide due to LRTls. [3] 
It is also estimated that in the United States, at least 500,000 hospitalizations 
occur each year with an estimated cost of $8.4 billion and with an additional 
$8.4 billion spent on community acquired pneumonia. [4] 
These infections are mainly caused by Streptococcus pneumoniae. Other 
pathogens may include Haemophilus influenzae, Moraxella catarhalis, or in 
some cases, viruses. [5] Antibiotics are usually recommended in these kinds 
of bacterial infections and the choice of antibiotic depends on the causing 
pathogen, and ranges from inexpensive first generation penicillins to more 
costly broad spectrum drugs such as fluoroquinolones. [5, 6] 
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The case is different for bronchitis and URTls since most of these conditions 
are not life threatening and they are usually caused by a virus, especially in 
acute illness. However, bacteria (e.g., Streptococcus pneumoniae) may be 
behind the infection in chronic illness. [7] For that reason, antibiotics are 
usually not indicated in acute infections, regardless on whether or not it is 
caused by a virus or a bacteria, since in most cases the illness resolves 
naturally and fast. [8] It is also important to note that antibiotics have not been 
shown to improve the clinical outcome of these patients. [1, 2] However, 
' patients with chronic bronchitis and some patients with chronic sinusitis and/or 
pharyngitis may still benefit from an antibiotic. [7] 
Many studies have demonstrated the inappropriate overutilization of antibiotics 
in certain acute RTls. [9, 10] In 1998 it was estimated that 76 million office 
visits for acute RTls resulted in 41 million antibiotic prescriptions. This was 
55% (22.6 million) more prescriptions than were expected to be used, with an 
associated cost of approximately $726 million. [11] Another study showed that 
between 1989 and 1999 there were 6.7 million annual office visits by sore 
throat (pharyngitis) patients, where approximately three quarters of adults 
(73%) were prescribed an antibiotic and 68% of the prescribed antibiotics were 
for non recommended use. The study also showed that broad spectrum and 
more expensive antibiotics are frequently used. [12] 
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The overutilization and inappropriate use of antibiotics in the community has 
not only led to higher treatment costs but has consequently led to the 
emergence of antibiotic resistant bacteria, which is becoming an epidemic and 
global problem. [7, 13-15] That is especially noted for one of the most common 
respiratory tract pathogen Streptococcus pneumoniae. However, resistance is 
not limited to one pathogen, it also includes resistance to Haemophilus 
influenzae, Moraxella catarhalis, and other bacteria. [13] The level and the 
mechanism of bacteria resistance to antibiotics vary between different 
' antibiotic classes. [13] 
Many factors have played a role in the over prescribing of antibiotics. Patients, 
for instance, have an expectation of receiving an antibiotic and are 
consequentially pressure their physician to prescribe one. They may also be 
financially responsible for a low or no copayment for their medications which 
may give them more incentive to fill the prescription.[16, 17] Physicians, on the 
other hand, try to meet the expectation of their patients and try to avoid any 
liability in the case of treatment failure, leading them to prescribe broad 
spectrum antibiotics. [18] Other factors may include the health care system 
structure, formularies and prescribing restrictions.[19] Also, directed 
advertising and marketing to physicians and consumers by pharmaceutical 
companies may lead to more prescription of high cost broad spectrum 
antibiotics.[20] 
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With the high cost associated with the overuse of antibiotics and for the fear of 
more antibiotic resistant bacteria it becomes important, from the perspective of 
the decision and policy makers, to explore more of the factors and 
components that may affect the prescribing pattern of antibiotics. It was the 
intent of this study to explore the effect of drug coverage type, copayment, and 
patient reported satisfaction with their health care when prescribed an 
antibiotic. So far, a limited number of studies have been conducted on these 
factors. 
Studies that explored the health insurance effect on prescribing antibiotics 
were either limited to a small group of patients, or did not look specifically at 
patients with acute respiratory tract infections. [21-23] Studies that examined 
the copayment effect demonstrated that an increase in the patient co-payment 
led to a decrease in the drug prescription and/or purchase. However, most of 
these studies were conducted on various classes of medications in a managed 
care organization setting and did not examine prescribing differences between 
different health care types. [24-26] 
The association between patient satisfaction and receiving an antibiotic was 
only demonstrated in two studies that have shown no association between 
getting an antibiotic and patient satisfaction. [27, 28] However, these studies 
had a limited number of patients enrolled and only examined satisfaction 
based on the patient expectation, and not on overall health care service. 
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The uniqueness of this study derives from its ability to use a large national 
survey that is actually designed to help study the effect of drug coverage, 
copayments and patients satisfaction on the use of health care services. The 
result of this study provided decision and policy makers with more insight and 
information on what may be done in practice to avoid excess cost and 
antibiotic resistance caused by inappropriate use of antibiotics. 
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Appendix B. Details of the methods used: 
Many statistical techniques have been used in this analysis, which include 
simple descriptive analysis about the study population in the different studies, 
it also include bivariate analysis between the different study variables, Chi-
square test have also been conducted to look if any variable have a significant 
effect on the main variable of interest. 
' Logistic regression was the main analytical test used in the three studies. 
Logistic regression models are so popular to analysts because of the ability of 
the model to describe a probability that is always some number between 0 and 
1. In epidemiological terms, such a probability gives the risk of an individual 
getting a disease or a condition when exposed to any risk factor.[1] 
Several techniques were used to develop the final logistic regression models. 
First, variables used in the study were dichotomized and dummy variables 
created for many of the variables. Second, univariate logistic regression was 
used to evaluate the relative contribution of each independent variable on 
predicting the influence of the main independent variable. Third , assessment 
of possible interaction terms (effect modifiers) was done between the primary 
independent variable and all other variables. Three, two, and one term 
interactions were completed and the decision was made on whether there was 
an interaction by examining at the log likelihood ratios in the chunk test. 
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The fourth technique used was testing for multi-collinearity and that was 
completed to examine the highly correlated variables and, if necessary, 
remove any variable from the model. That was accomplished by examining the 
condition index in the SAS output. Finally, testing for potential confounders 
that may influence our final model was carried out by comparing the B 
(coefficient) of the primary independent variable of the full model to each 
reduced model (i.e., a model missing on variable). 
' All statistical analysis were carried out using SAS version 8.1 (SAS Institute, 
Cary North Carolina) and SUDAAN software package (Research Triangle 
Institute, Research Triangle Park, North Carolina), both licensed to the 
University of Rhode Island. The results of the study have been weighted to 
generate 1996 national estimates. Many references for SAS and SUDAAN 
programming, methodology, and interpreting results have used.[1-5] 
Weighting of the study population was completed using SUDAAN, which is a 
unique software package. It enables us to use survey and other types of 
clustered data (e.g., MEPS) to obtain estimates using the proper design 
parameters (e.g., variance estimation strata and the variance estimation PSU) 
and to compute appropriate standard errors of these estimates. Other software 
packages (e.g. , SAS) are not able to use complex sample designs when 
computing variance estimates and test statistics.[5] 
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